Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours

NCT06193902 is registered in ClinicalTrials.gov with Leucid Bio as lead sponsor.

NCT NCT06193902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06193902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours
Lead sponsor
Leucid Bio
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 13, 2023
Completion date
May 31, 2029
Enrollment
17 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tumor, solid